CompletedPhase 2NCT01705795
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Studying Bullous pemphigoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Principal Investigator
- Dagmar SimonInselspital, Bern University Hospital
- Intervention
- Mepolizumab (a-IL-5 antibody)(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (1)
- Dep. of Dermatology, Bern University Hospital, Bern, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01705795 on ClinicalTrials.govOther trials for Bullous pemphigoid
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06291350Peridontal and Intestinal Microbiota in Patients With Gingival Scarring PemphigoidCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06479018Deciphering IL-17-dependant Inflammatory Response in Bullous PemphigoidCHU de Reims
- RECRUITINGNCT04198740Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT03295383Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidUniversity Hospital, Rouen